To assess the utility of CDCA3 as a tool to identify platinum-based chemotherapy response in NSCLC, we evaluated available patient data for correlations with gene signatures or DNA-based measures of genome instability. This evidence concerns the gene CDCA3 and non-small cell lung carcinoma.